July 26, 2018
Neurodegeneration may be tied to drainage issues in the brain
PureTech Health’s new internal programme focused on treating central nervous system (CNS) disorders via modulation of the brain’s lymphatic system,…
Pharmaceuticals, Biotechnology and Life Sciences
Category: Approval
July 26, 2018
WuXi’s API production site in china passes USFDA’s inspection
WuXi STA Pharmaceutical’s Active Pharmaceutical Ingredient (API) production site in China, at Jinshan, Shanghai, has passed its fourth inspection from…
July 25, 2018
resTORbio with positive results in Phase 2b trial of inhibitor RTB101
PureTech Health’s independent affiliate, resTORbio reported positive topline results from its Phase 2b clinical study with TORC1 inhibitor, that enrolled…
July 25, 2018
Midatexh Pharma expects 16% revenues increase in first half of the year
Midatech Pharma said in its trading update it remains on track to meet market expectations for 2018, as it expects…
July 24, 2018
Cheplapharm to deal Atacand in 28 European countries, AZ nets $200M
AstraZeneca will sell the commercial rights to prescription medicine for the treatment of heart failure and hypertension, Atacand and Atacand Plus…
July 24, 2018
Idorsia expects non-GAAP operating expenses for 2018 to be around 390 million Swiss francs
Idorsia operated with US GAAP 155 million CHP ($156M) net loss for the first half of 2018. According to the…
July 23, 2018
Novartis extends agreement with the WHO for the donation of Egaten for the treatment of liver fluke
Novartis has signed a renewed memorandum of understanding with the World Health Organization (WHO) to extend its drug donation for Egaten…
July 19, 2018
Tradjenta’s Carmelina cardiovascular outcome trial meets primary endpoint
Boehringer Ingelheim and Eli Lilly released the positive top-line results from the trial, which evaluated the impact of treatment with…
July 12, 2018
NICE backs EUSA Pharma’s Qarziba for children with high-risk neuroblastoma
The National Institute for Health and Care Excellence (NICE) has recommended the use of the EUSA Pharma’s targeted cancer immunotherapy, QARZIBA…
July 10, 2018
Myocant Sciences complets screening patients for heavy menstrual bleeding study
Myovant Sciences has completed screening patients for its LIBERTY 1 study, the first of two Phase 3 replicate studies evaluating…